

References

1. Leung DYM, Eichenfield LF, Boguniewicz M. Atopic dermatitis (Atopic eczema). In: Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffel DJ, Wolff K, editors. Fitzpatrick's dermatology in general medicine. 8th ed. New York: McGraw-Hill; 2012. p.165-82.
2. Nutten S. Atopic dermatitis: global epidemiology and risk factors. *Ann Nutr Metab* 2015; 66(suppl 1): 8-16.
3. Fathi G, Saber K, Shaaban F, Fakhry D. Increased urinary leukotriene E4 and its correlation to severity and laboratory markers of atopic dermatitis in children. *J Med Sci* 2007; 7(2): 216-21.
4. Hishinuma T, Suzuki N, Aiba S, Tagami H, Mizugaki M. Increased urinary leukotriene E4 excretion in patients with atopic dermatitis. *Br J Dermatol* 2001; 144: 19-23.
5. Liu M, Yokomizo T. The role of leukotrienes in allergic diseases. *Allergol Int* 2015; 64: 17-26.
6. Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors, emerging concepts. *Allergy Asthma Immunol Res* 2014; 6(4): 288-95.
7. Adamek-Guzik T, Guzik TJ, Czerniawska-Mysik G, Korpanty G, Mastalerz L, Radwan J, et al. Urinary leukotriene levels are increased during atopic eczema/dermatitis syndrome, relation to clinical status. *Allergy* 2002; 57: 732-6.
8. Mastalerz L, Kumik J. Antileukotriene drugs in the treatment of asthma. *Pol Arch Med Wewn* 2010; 120(3): 103-8.
9. Eustachio N, D'Erasmus M, Di Leo E, Calogiuri G, Montinaro V, Ferrannini A, et al. The employment of leukotriene antagonists in cutaneous diseases belonging to allergological field. *Mediators Inflamm (serial online)* 2010 [cited on 2016 Aug 30]; [6 screens]. Available from: <https://www.hindawi.com/journals/mi/2010/628171/>
10. Sala A, Voelkel N, Maclouf J, Murphy RC. Leukotriene E4 elimination and metabolism in normal human subjects. *J Biol Chem* 1990; 265(35): 21771-8.
11. Haeggström JZ, Funk DJ. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. *Chem Rev* 2011; 111: 5866-98.
12. Hon KLE, Leung TF, Ma KC, Li AM, Wong Y, Li CY, et al. Urinary leukotriene E4 correlates with severity of atopic dermatitis in children. *Clin Exp Dermatol* 2004; 29: 277-81.
13. Emam EK, Salem SAM, Fouad DA. Study of urinary leukotriene E4 in atopic dermatitis: relation to disease severity. *Egypt J Pediatr Allergy Immunol* 2003; 1(2): 134-9.
14. Mastalerz L, Kumik J. Antileukotriene drugs in the treatment of asthma. *Pol Arch Med Wewn* 2010; 120(3): 103-8.
15. Eustachio N, D'Erasmus M, Di Leo E, Calogiuri G, Montinaro V, Ferrannini A, et al. The employment of leukotriene antagonists in cutaneous diseases belonging to allergological field. *Mediators Inflamm (serial online)* 2010 [cited on 2016 Aug 30]; [6 screens]. Available from: <https://www.hindawi.com/journals/mi/2010/628171/>

Non-commercial use only